ArticleCureus2026
Association of Mean Corpuscular Hemoglobin Concentration With Mortality in Patients With Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile mean corpuscular hemoglobin concentration (MCHC) correlates with prognosis in various critical conditions, its relationship with mortality in ICU patients with cancer remains underexplored.
methodsWe included 20,055 cancer patients with available MCHC values. Data extracted included demographics, comorbidities, laboratory parameters within 24 hours, illness severity scores, and vasoactive medication use. Primary outcomes were 30-day and 90-day in-hospital mortality. Kaplan-Meier analysis and multivariable Cox proportional hazards models assessed the association between MCHC and mortality.
resultsKaplan-Meier curves showed significant survival differences across MCHC quartiles, with higher MCHC associated with better survival. In fully adjusted Cox models, each unit increase in MCHC was associated with lower mortality risk at 30 days (HR: 0.86, 95% CI: 0.83-0.89) and 90 days (HR: 0.86, 95% CI: 0.83-0.88). Patients in the highest MCHC quartile had significantly lower mortality risk compared to the lowest quartile (30-day - HR: 0.56, 95% CI: 0.49-0.63; 90-day - HR: 0.55, 95% CI: 0.49-0.62). Subgroup analyses confirmed consistent associations across all clinical strata.
conclusionLower MCHC levels at ICU admission are independently associated with increased short-term and medium-term mortality in critically ill cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.